{
    "clinical_study": {
        "@rank": "142977", 
        "acronym": "NEO ER 11-05", 
        "arm_group": {
            "arm_group_label": "Anastrozole", 
            "arm_group_type": "Experimental", 
            "description": "All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery"
        }, 
        "brief_summary": {
            "textblock": "1. Women with operable breast cancer with a 2-8 week preoperative waiting period will\n           accept preoperative therapy trials and specifically taking a standard drug for breast\n           cancer such as anastrozole in this study\n\n        2. Short term anastrozole treatment will induce measurable changes in biomarker levels\n           (ER, PR, Her2, Ki67) within the tumor.\n\n        3. Degree of response to short term anastrozole varies with a) duration of treatment and\n           b) breast cancer subtype (based on initial pre-treatment biomarker status)"
        }, 
        "brief_title": "Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Newly diagnosed postmenopausal women (Women are considered post-menopausal and not of\n             child bearing potential if they have had 12 months of natural (spontaneous)\n             amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of\n             vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels >\n             40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with\n             or without hysterectomy) at least six weeks ago.)\n\n          2. Confirmation of estrogen receptor positive invasive carcinoma on core biopsy\n\n          3. Patients whose cancers are palpable and have been deemed to be \"operable\" by the\n             surgeon\n\n          4. Surgery is planned for the next 2-8 weeks.\n\n        Exclusion Criteria:\n\n          1. History of hormone replacement therapy in the last 6 months\n\n          2. Previous treatment by tamoxifen or aromatase inhibitor treatment in six months\n\n          3. Known hypersensitivity or contraindications to aromatase inhibitors\n\n          4. Known metastatic disease on presentation\n\n          5. Recurrent breast cancer\n\n          6. Inability to give informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972984", 
            "org_study_id": "2011712-01H"
        }, 
        "intervention": {
            "arm_group_label": "Anastrozole", 
            "description": "Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.", 
            "intervention_name": "Anastrozole", 
            "intervention_type": "Drug", 
            "other_name": "Arimidex"
        }, 
        "intervention_browse": {
            "mesh_term": "Anastrozole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Estrogen receptor positive", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ottawa", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "K1H 8L6"
                }, 
                "name": "The Ottawa Hospital"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "The NEO (NEOADJUVANT ENDOCRINE OUTCOMES) TRIAL: Neoadjuvant Endocrine Therapy for Primary Breast Cancer: Investigation of Clinical and Translational Outcomes", 
        "overall_official": {
            "affiliation": "The Ottawa Hospital Cancer Centre", 
            "last_name": "Angel Arnaout, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants are on study from the time their eligibility is confirmed until the time of their surgery which could be up to 8 weeks. This is a feasibility study and therefore once the study is closed to accrual the percent of women who signed consent and remained on study until their surgery versus those who withdraw will be determined.", 
            "measure": "Percentage of patients who fit the eligibility criteria that consent to the study; withdraw after consent from the study.", 
            "safety_issue": "No", 
            "time_frame": "up to 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972984"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "All biomarker results will be analyzed at study closure when participant #20 has received surgery.", 
            "measure": "Measure the changes in ER, PR, Her2 and Ki67 labelling index on pre- and post treatment tumor tissue", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 months"
        }, 
        "source": "Ottawa Hospital Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Breast Cancer Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ottawa Hospital Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}